Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of clinically and morphologically heterogeneous lymphoid proliferations of various clonal compositions that are observed after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. The majority of PTLD cases are associated with Epstein-Barr virus (EBV) infection, while overt peripheral blood (PB) or bone marrow (BM) involvement in PTLD is uncommon in early lesions. We report a 38-year-old woman with EBV-related PTLD, with BM and PB involvement, who presented with peripheral lymphocytosis as an early lesion 1 month after haploidentical HSCT for Philadelphia chromosome-positive acute lymphoblastic leukemia was performed during first complete remission. Although PB or BM involvement of PTLD after HSCT is uncommon in early lesions, peripheral lymphocytosis can be an initial presenting manifestation of PTLD, as in this case. (Korean J Med 2015;89:243-248) 
INTRODUCTION
Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of clinically and morphologically heterogeneous lymphoid proliferations of various clonal compositions that are seen after bone marrow (BM) or solid organ transplantation (SOT) [1] . Although PTLDs represent rare complications (< 1%) after allogeneic hematopoietic stem cell transplantation (HSCT), known risk factors include donor/recipient human leukocyte antigen (HLA) mismatch, T cell-depleted hematopoietic stem cell grafts, use of anti-thymocyte globulin (ATG), and graft-versus-host disease (GVHD) [2] . The reported incidence for patients with these risk factors is as high as 15-25% [1, 2] . The pathogenesis of PTLD in most patients appears to be related to B-cell proliferation induced by Epstein-Barr virus (EBV) infection. In primary or secondary immunodeficiency, acute EBV infection leads to a poly- which is a life-threatening complication [3] . In patients who undergo HSCT, EBV-associated PTLD is classified according to the time of onset: in the early post-transplantation period (< 1 year) or as a late manifestation (> 1 year) [3] . Early-onset PTLDs are usually EBV-positive, histologically heterogeneous, include most polyclonal mononucleosis-like forms, and are associated with higher peripheral blood (PB) EBV DNA levels [4] . Extranodal involvement is common in PTLD, whereas PB and BM involvement is extremely rare, with only a few reports of BM PTLD in recipients of BM and solid organ transplants [5, 6] . Here, we describe the case of a 38-year-old woman with early-onset EBVassociated PTLD in PB and BM after haploidentical HSCT for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
CASE REPORT
A 38-year-old woman was diagnosed with Ph+ ALL in October 2013. A BM chromosome study gave uninterpretable results and fluorescence in situ hybridization revealed t (9;22) and de l (9p21). 
DISCUSSION
Epstein-Barr virus-associated PTLD is a well-documented complication in primary or secondary immunocompromised patients.
The incidence of EBV-associated PTLD after HSCT is generally < 1%, but intensive immunosuppression, as in HLA-mismatched and T cell-depleted recipients, may markedly increase the risk of PTLD [1] . Park et al. [7] investigated the incidence and clinical progress of PTLD after allogeneic HSCT. The overall incidence of PTLD was 0.6% and there were no postmortem diagnoses.
The overall response rate was 71.4% and the mortality rate was 42.8%. HSCT is reported to have a relatively low incidence of EBV lymphoproliferative disorder (LPD). Recently, Gross et al. [8] estimated a 15.7% risk of LPD in HLA-mismatched and T celldepleted recipients at 6 months after transplant and suggested that older donor age was an independent risk factor for PTLD.
Reddiconto et al. [9] investigated the incidence of EBV-related complications in 335 patients undergoing HSCT and documented an overall rate of 4.5%, with an incidence of 3.3% in myeloa- Previous studies have reported using treatments such as immunosuppression reduction, cytotoxic chemotherapy, monoclonal antibody therapy, radiation therapy, cellular immunotherapy, antiviral therapy, and cytokine therapy [2] . A massive reduction of immunosuppression represents the most important treatment.
Recent results with anti-B-cell monoclonal antibody therapy, in conjunction with rituximab and cytotoxic T lymphocyte therapy, have been quite promising, with many patients achieving longterm relapse-free survival [2] . In lymphoma with positive EBV markers, antiviral therapy with acyclovir or ganciclovir can be considered. However, although acyclovir and ganciclovir inhibit viral DNA polymerase, they have no effect on cellular DNA polymerase and do not inhibit in vitro EBV-induced transformation.
Consequently, there is no obvious role for acyclovir or ganciclovir as either prophylaxis or treatment for PTLD. In our patient, we reduced immunosuppression and administered steroid, which proved effective against PTLD.
Although PTLD is rare during the early post-transplantation period, we should consider the possibility of PTLD when encountering early peripheral lymphocytosis with no clear cause.
Since there is no method for predicting PTLD, and PTLD in HSCT tends to progress rapidly, it is often fatal relatively early after transplantation; an early diagnosis of PTLD is important for prompt therapy and to decrease mortality. Some studies have reported that the early mortality rate for PTLD after HSCT approached 90% [2] . Therefore, if there is abnormal peripheral lymphocyte proliferation in the early phase of allogeneic HSCT, an EBV activity test (EBV quantitative PCR, EBV-VCA or EBV nuclear antigen), lymph node biopsy, and FDG-PET should be performed. When PTLD is confirmed, the immunosuppressive dose should be reduced first, which often eliminates the disease permanently. Additional therapies should be tailored to the individual patient and clinical situation.
In conclusion, PTLDs are fascinating disorders that clearly highlight the roles of the immune system and viral infection in the development of malignancy. The pathogenesis of EBV-associated PTLD is thought to be multifactorial and is not well understood. Therefore, supportive care and adopted immunotherapy should be integrated into the treatment regimen of this aggressive and often fatal disease. Based on our experience, further long-term studies should examine patients with early peripheral lymphocytosis and EBV-associated PTLD after allogeneic HSCT. Moreover, guidelines should be prepared that enable the prediction of this complication after haploidentical HSCT.
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